Outstanding Lifetime Achievement Award in Clinical Chemistry and Laboratory Medicine
Dr. Shaw is professor of pathology and laboratory medicine and interim director of the clinical chemistry laboratory at the University of Pennsylvania hospital and school of medicine in Philadelphia. One of his primary scientific contributions has come in the area of Alzheimer’s disease biomarker research. He developed the Alzheimer’s disease neuroimaging initiative (ADNI), which is one of the world’s largest public-private research partnerships, with more than $140 million in funding from the National Institutes of Health, pharmaceutical companies, and foundations. He currently co-directs the federally funded ADNI biomarker core laboratory at the University of Pennsylvania, as well as the Parkinson’s progression markers initiative. He has also been a pioneer in therapeutic drug monitoring. He established a toxicology and therapeutic drug monitoring laboratory at the University of Pennsylvania and participated in several international consensus panels devoted to defining best practices. He has served as president of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology, served on the NCCLS committee on toxicology and drug monitoring, and was the lead editor for the first edition of the text, The Clinical Toxicology Laboratory: Contemporary Practice of Poisoning Evaluation. He has also been active in service, chairing the scientific and technical affairs committee and serving on the board of directors of the National Academy of Clinical Biochemistry. He has chaired the the Association for Diagnostics & Laboratory Medicine’s (formerly AACC) Therapeutic Drug Monitoring and Clinical Toxicology Division. Dr. Shaw has served on the boards of editors of Clinical Chemistry, Therapeutic Drug Monitoring, and Clinical Biochemistry. He has published more than 200 peer-reviewed articles on a wide variety of topics.